New pill RAP-219 tested for stubborn seizures
NCT ID NCT06377930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an investigational drug called RAP-219 in 30 adults with refractory focal epilepsy—seizures that don't respond well to current treatments. Participants took RAP-219 tablets to see if it safely reduces seizure frequency. The trial is now complete, and results will help determine if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAP-219 oral tablet
What this could lead to
If successful, RAP-219 could offer a new treatment option for people with hard-to-control focal epilepsy, potentially reducing seizure frequency.
What could go wrong
This is a small, early-phase (Phase 2A) open-label study with no placebo group, so results may not confirm effectiveness. Side effects and lack of long-term data are also concerns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 770300, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho, 83702, United States
-
IU Health Neuroscience Center, Goodman Hall
Indianapolis, Indiana, 46202, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NYU Langone Comprehensive Epilepsy Center
New York, New York, 10016, United States
-
The University of Kansas Medical Center Epilepsy Clinic
Kansas City, Kansas, 66160, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Pennsylvania - Department of Neurology
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Health Science Center, Houston
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Yale University
New Haven, Connecticut, 06519, United States